Phaseline

Companies › Op-T

Op-T: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OPT101–Phase 2Type I DiabetesAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06964087OPT101Phase 2Type I DiabetesMetabolic and endocrineAug 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Portal Therapeutics Housey Healthcare ULC Mankind Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.